| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75b86e50a7529f6158517db14a0b81df |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16C20-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16C20-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-20 |
| filingDate |
2013-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f4a1c6d1005fe9c5cc6d1d5698de8b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_990dcfcc9c6139e34cc4c982954cfe4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4963747728a49a9ed608ab79e2f3b19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7544aab5575bdb92c1c8acd2fd8ab8c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ba3f92b1f1ad7fd633dd225bcb86982
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84ca17a611f49acae0297e79274e4bf8 |
| publicationDate |
2019-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10460831-B2 |
| titleOfInvention |
Predictive outcome assessment for chemotherapy with neoadjuvant bevacizumab |
| abstract |
In a predictive outcome assessment test for predicting whether a patient undergoing a breast cancer treatment regimen will achieve pathological complete response (pCR), differential gene expression level information are generated for an input set of genes belonging to the TGF-β signaling pathway. The differential gene expression level information compares baseline gene expression level information from a baseline sample (70) of a breast tumor of a patient acquired before initiating (71) a breast cancer therapy regimen to the patient and response gene expression level information from a response sample (72) of the breast tumor acquired after initiating the breast cancer therapy regimen by administering a first dose of bevacizumab to the patient. A pCR prediction for the patient is computed based on the differential gene expression level information for the input set of genes belonging to the TGF-β signaling pathway. Related predictive outcome assessment test development methods are also disclosed. |
| priorityDate |
2012-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |